NEUROCRINE BIOSCIENCES INC (NBIX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $151.50M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $193.40M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $239.00M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $145.60M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $151.50M | (m) | $959.00M | (m) | $7.80M* | $136.40M* | (m) | (m) | $439.70M | $17.80M |
| 2026-03-31 | Reported | (m) | $193.40M | (m) | $814.50M | (m) | $9.10M | $145.80M | $13.80M | (m) | $318.50M | $48.90M |
| 2025-09-30 | Reported | (m) | $239.00M | (m) | $794.90M | (m) | $13.20M* | $227.50M* | $14.00M | (m) | $291.60M | $82.30M |
| 2025-06-30 | Reported | (m) | $145.60M | (m) | $687.50M | (m) | $12.50M* | $102.00M* | $11.30M | (m) | $286.30M | $52.00M |
| 2025-03-31 | Reported | (m) | $23.60M | (m) | $572.60M | (m) | $10.70M | $64.80M | $9.20M | (m) | $276.50M | $6.80M |
| 2024-09-30 | Reported | (m) | $183.80M | (m) | $622.10M | (m) | $8.10M* | $158.00M* | $8.00M | (m) | $234.30M | $60.50M |
| 2024-06-30 | Reported | (m) | $145.40M | (m) | $590.20M | (m) | $11.60M* | $64.60M* | $9.20M | (m) | $242.00M | $33.60M |
| 2024-03-31 | Reported | (m) | $99.30M | (m) | $515.30M | (m) | $11.20M | $130.30M | $7.50M | (m) | $243.10M | -$8.90M |
| 2023-09-30 | Reported | (m) | $141.20M | (m) | $498.80M | (m) | $7.60M* | $212.00M* | $11.20M | (m) | $204.20M | $32.50M |
| 2023-06-30 | Reported | (m) | $73.60M | (m) | $452.70M | (m) | $6.80M* | $179.60M* | $11.50M | (m) | $221.80M | $26.10M |
| 2023-03-31 | Reported | (m) | -$114.20M | (m) | $420.40M | (m) | $8.50M | -$125.20M | $8.50M | (m) | $242.70M | -$26.70M |
| 2022-09-30 | Reported | (m) | $87.80M | (m) | $387.90M | (m) | -$1.70M* | $98.80M* | $6.10M | (m) | $186.30M | $29.40M |
| 2022-06-30 | Reported | (m) | $54.70M | (m) | $378.20M | (m) | $8.80M* | $138.10M* | $4.80M | (m) | $182.80M | -$6.40M |
| 2022-03-31 | Reported | (m) | $3.10M | (m) | $310.60M | (m) | $7.60M | -$40.50M | $4.60M | (m) | $200.70M | $7.50M |
| 2021-09-30 | Reported | (m) | $44.50M | (m) | $296.00M | (m) | $5.70M* | $61.80M* | $4.20M | (m) | $154.60M | $8.00M |
| 2021-06-30 | Reported | (m) | $62.80M | (m) | $288.90M | (m) | $4.30M* | $103.20M* | $3.10M | (m) | $143.20M | $15.20M |
| 2021-03-31 | Reported | (m) | $31.50M | (m) | $236.60M | (m) | $4.50M | $87.30M | $2.90M | $73.20M | $129.00M | -$4.90M |
| 2020-09-30 | Reported | (m) | -$44.30M | (m) | $258.50M | (m) | $400.00K* | -$20.40M* | $2.70M | (m) | $112.50M | $500.00K |
| 2020-06-30 | Reported | (m) | $76.60M | (m) | $302.40M | (m) | $4.70M* | $118.90M* | $2.40M | (m) | $96.50M | $3.60M |
| 2020-03-31 | Reported | (m) | $58.90M | (m) | $237.10M | (m) | $1.30M | $35.50M | $2.10M | $58.30M | $117.80M | $1.50M |
| 2019-09-30 | Reported | (m) | $90.10M | (m) | $222.10M | (m) | $3.50M* | $97.80M* | $2.20M | (m) | $84.50M | $4.60M |
| 2019-06-30 | Reported | (m) | $34.40M | (m) | $183.50M | (m) | $4.50M* | $64.20M* | $1.60M | $61.69M | $80.80M | $800.00K |
| 2019-03-31 | Reported | (m) | -$101.00M | (m) | $138.40M | (m) | $3.90M | -$112.50M | $1.13M | $37.65M | $87.50M | -$500.00K |
| 2018-09-30 | Reported | (m) | $54.32M | (m) | $151.76M | (m) | $12.36M* | $68.92M* | $1.55M | $35.48M | $60.40M | (m) |
| 2018-06-30 | Reported | (m) | -$1.85M | (m) | $96.91M | (m) | $4.64M* | $20.48M* | $854.00K | $36.99M | $60.91M | (m) |
| 2018-03-31 | Reported | (m) | -$37.45M | (m) | $71.09M | (m) | $1.80M | -$38.49M | $950.00K | $48.95M | $58.64M | (m) |
| 2017-09-30 | Reported | (m) | -$6.00M | (m) | $60.77M | (m) | $2.80M* | -$9.31M* | $433.00K | $22.46M | $43.87M | (m) |
| 2017-06-30 | Reported | (m) | -$57.27M | (m) | $6.33M | (m) | $397.00K* | (m) | $61.00K | $21.87M | $41.67M | (m) |
| 2017-03-31 | Reported | (m) | -$79.93M | (m) | $0.00 | (m) | $1.36M | (m) | (m) | $51.88M | $28.05M | (m) |
| 2016-09-30 | Reported | (m) | -$38.44M | (m) | (m) | (m) | $777.00K* | (m) | (m) | $20.94M | $17.49M | (m) |
| 2016-06-30 | Reported | (m) | -$41.83M | (m) | (m) | (m) | $2.24M* | (m) | (m) | $26.86M | $14.96M | (m) |
| 2016-03-31 | Reported | (m) | -$20.86M | (m) | (m) | (m) | $741.00K | (m) | (m) | $23.90M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$35.84M | (m) | (m) | (m) | $316.00K* | (m) | (m) | $24.39M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$25.32M | (m) | (m) | (m) | $510.00K* | (m) | (m) | $18.72M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$2.29M | (m) | (m) | (m) | $280.00K | (m) | (m) | $16.57M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$16.86M | (m) | (m) | (m) | $269.00K* | (m) | (m) | $12.19M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$14.36M | (m) | (m) | (m) | $649.00K* | (m) | (m) | $10.16M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$12.72M | (m) | (m) | (m) | $255.00K | (m) | (m) | $8.57M | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$12.01M | (m) | (m) | (m) | $31.00K* | -$10.78M* | (m) | $9.49M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$13.17M | (m) | (m) | (m) | $264.00K* | -$9.86M* | (m) | $10.53M | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$12.97M | (m) | (m) | (m) | $59.00K | $1.91M | (m) | $10.31M | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$3.96M | (m) | (m) | (m) | $335.00K* | -$8.30M* | (m) | $9.86M | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$1.38M | (m) | (m) | (m) | $190.00K* | -$6.88M* | (m) | $8.82M | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$1.79M | (m) | (m) | (m) | $404.00K | -$11.20M | (m) | $9.39M | (m) | (m) |
| 2011-09-30 | Reported | (m) | $30.44M | (m) | (m) | (m) | $562.00K* | $2.77M* | (m) | $7.46M | (m) | (m) |
| 2011-06-30 | Reported | (m) | $1.10M | (m) | (m) | (m) | $128.00K* | -$5.91M* | (m) | $8.18M | (m) | (m) |
| 2011-03-31 | Reported | (m) | $1.94M | (m) | (m) | (m) | $20.00K | -$8.58M | (m) | $7.32M | (m) | (m) |
| 2010-09-30 | Reported | (m) | $2.47M | (m) | (m) | (m) | $86.00K* | $1.14M* | (m) | $8.23M | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$5.89M | (m) | (m) | (m) | (m) | (m) | (m) | $7.28M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $619.10M | (m) | $2.86B | (m) | $34.00M | $782.70M | $52.10M | (m) | $1.16B | $226.80M |
| 2024-12-31 | Reported | (m) | $570.50M | (m) | $2.36B | (m) | $38.20M | $595.40M | $34.00M | (m) | $1.01B | $144.70M |
| 2023-12-31 | Reported | (m) | $250.90M | (m) | $1.89B | (m) | $28.30M | $389.90M | $39.70M | (m) | $887.60M | $82.40M |
| 2022-12-31 | Reported | (m) | $249.00M | (m) | $1.49B | (m) | $16.50M | $339.40M | $23.20M | (m) | $752.70M | $59.40M |
| 2021-12-31 | Reported | (m) | $102.50M | (m) | $1.13B | (m) | $23.40M | $256.50M | $14.30M | (m) | $583.30M | $11.80M |
| 2020-12-31 | Reported | (m) | $163.00M | (m) | $1.05B | (m) | $10.90M | $228.50M | $10.10M | (m) | $433.30M | -$300.60M |
| 2019-12-31 | Reported | (m) | $72.30M | (m) | $788.10M | (m) | $14.70M | $147.00M | (m) | (m) | $354.10M | $9.50M |
| 2018-12-31 | Reported | (m) | $36.80M | (m) | $451.20M | (m) | $24.80M | $101.40M | $4.89M | $160.52M | $248.90M | $700.00K |
| 2017-12-31 | Reported | (m) | -$131.36M | (m) | $161.63M | (m) | $6.94M | -$94.33M | $1.25M | $121.83M | $169.91M | $0.00 |
| 2016-12-31 | Reported | (m) | -$147.37M | (m) | $15.00M | (m) | $4.11M | -$106.18M | $0.00 | $94.29M | $68.08M | $0.00 |
| 2015-12-31 | Reported | (m) | -$94.20M | (m) | (m) | (m) | $1.93M | (m) | (m) | $81.49M | $32.48M | $0.00 |
| 2014-12-31 | Reported | (m) | -$64.41M | (m) | (m) | (m) | $1.61M | (m) | (m) | $46.42M | (m) | $0.00 |
| 2013-12-31 | Reported | (m) | -$49.68M | (m) | (m) | (m) | $545.00K | -$29.61M | (m) | $39.25M | (m) | $0.00 |
| 2012-12-31 | Reported | (m) | $1.45M | (m) | (m) | (m) | $971.00K | -$35.29M | (m) | $37.16M | (m) | $0.00 |
| 2011-12-31 | Reported | (m) | $33.92M | (m) | (m) | (m) | $750.00K | -$698.00K | (m) | $30.95M | (m) | $0.00 |
| 2010-12-31 | Reported | (m) | -$13.72M | (m) | (m) | (m) | $315.00K | $49.94M | (m) | $31.15M | (m) | (m) |
| 2009-12-31 | Reported | (m) | -$53.67M | (m) | (m) | (m) | $35.00K | -$53.09M | (m) | $33.72M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |